Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

CTS Portland Implements New Laboratory Information System

On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...

Read More >

Creative Testing Solutions and Grifols Forge New Testing Partnership

Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...

Read More >

Exhibiting at AABB Annual Meeting- Booth 1038

We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...

Read More >

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 conva...

Read More >

CTS Implements HLA Class I and II Testing on the Gemini

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...

Read More >

COVID-19 Antibody Testing Frequently Asked Questions

The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...

Read More >